Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly's Growth In Diabetes Gives It Market Leading Position

Executive Summary

The diabetes giant has overtaken competition in key areas due to successes across several classes and strong data.

You may also be interested in...



Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance

Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.

2Q Pharma Results Preview: What Lies Ahead

The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.

ADA: EMPA-REG Continues To Impress With More Data For Lilly/Boehringer's Jardiance

Eli Lilly & Co. and Boehringer Ingelheim GMBH have once again excited doctors with further analysis presented at the American Diabetes Association's meeting for Jardiance (empagliflozin) from the EMPA-REG cardiovascular outcomes study – this time showing benefits for kidney protection.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel